Search results for "From ACP Journal Club"
BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes
The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/12/09/9.htm
9 Dec 2022
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/06/08/6.htm
8 Jun 2018
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of macroalbuminuria, with measures of renal impairment remaining unchanged.
https://diabetes.acponline.org/archives/2018/01/12/9.htm
12 Jan 2018
Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more
Hypertension treatment reduced mortality and myocardial infarction in diabetic patients with a systolic blood pressure of at least 140 mm Hg, a systematic review and meta-analysis found. However, in patients with lower baseline blood pressure (BP), treatment didn't affect overall mortality and was associated with increased cardiovascular mortality.
https://diabetes.acponline.org/archives/2016/07/15/6.htm
15 Jul 2016
Studies show benefits of glucagon-like peptide-1 receptor agonists
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
https://diabetes.acponline.org/archives/2019/10/11/7.htm
11 Oct 2019
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/09/08/6.htm
8 Sep 2017
In type 2 diabetes, a primary care–led weight management program increased weight loss and diabetes remission at 2 years
Primary care practices that want to adopt such an intervention for their patients will need a dietician or practice nurse to deliver an intensive weight loss program, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/8.htm
13 Sep 2019
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
The trial showed that an oral glucagon-like peptide-1–receptor analogue improved glycemic control compared to a dipeptidyl peptidase 4 inhibitor, but gastrointestinal side effects and cost remain barriers to use of the former class.
https://diabetes.acponline.org/archives/2019/09/13/7.htm
13 Sep 2019
Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes
While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high cardiovascular risk should receive agents with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/01/12/10.htm
12 Jan 2018
In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis
Taking canagliflozin, at a dose of either 100 mg or 300 mg per day, was associated with risk of diabetic ketoacidosis, according to a trial that randomized patients with type 1 diabetes to either of the doses or a placebo.
https://diabetes.acponline.org/archives/2016/08/12/5.htm
12 Aug 2016